Hematology Advisor
LightNews LightNews
banner
hematologyadvisor.bsky.social
Hematology Advisor
@hematologyadvisor.bsky.social
130 followers 140 following 240 posts
HematologyAdvisor.com is a trusted knowledge base of practical information and resources focused on hematology and critical care medicine.
Posts Replies Media Videos
hematologyadvisor.bsky.social
Risk stratification for risk of neutropenia, infections, and survival outcomes using CAR-HEMATOTOX score among patients with R/R LBCL receiving CAR T-cell therapy was reaffirmed in a larger, real-world cohort. Published in @bloodjournals.hematology.org.

https://bit.ly/4cmEMbk

#lymsm #lymphoma
Real-Word Population Further Validates CAR-HEMATOTOX for CAR-T Therapy
Utilizing the CAR-HEMATOTOX score among patients with R/R LBCL was reaffirmed in a larger, real-world cohort with respect to neutropenia.
bit.ly
February 12, 2026 at 2:21 AM
hematologyadvisor.bsky.social
An elevated L/M ratio at diagnosis may independently predict inferior outcomes in #myelodysplasticSyndromes, although this adverse impact may be overcome by allo-HSCT. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/4bpiF3D

#MDS
Elevated Lymphocyte-to-Monocyte Ratio May Predict Poor Outcomes in MDS
Among patients in the high L/M group, transcriptomic profiling of diagnostic marrow samples revealed downregulation of inflammatory pathways and the TP53 pathway, alongside enrichment of MYC targets.
bit.ly
February 10, 2026 at 6:11 PM
hematologyadvisor.bsky.social
Patients’ #financial resources affect their enrollment in #oncology #clinicaltrials to a greater degree than traditional demographic characteristics. Published in @cancertherapyadv.bsky.social.

https://bit.ly/3NRdKi7

#cancertrials
Financial Factors Affect Cancer Patients' Enrollment in Clinical Trials
Patients' financial resources affect their enrollment in oncology clinical trials to a greater degree than traditional demographic characteristics.
bit.ly
February 9, 2026 at 5:45 PM
hematologyadvisor.bsky.social
Efanesoctocog alfa has been successfully integrated into clinical practice for treating severe #hemophilia A, including patients previously excluded from trials, such as those with FVIII inhibitors or prior emicizumab use. From @rarediseaseadvisor.bsky.social.

https://bit.ly/4k5pkCc

#hemonc
Real-World Use of Efanesoctocog Alfa Shows Benefit in Severe Hemophilia A
Efanesoctocog alfa improves hemostasis, reduces bleeding, and enhances quality of life for patients with severe hemophilia A, including those previously excluded from trials.
bit.ly
February 8, 2026 at 6:43 PM
hematologyadvisor.bsky.social
A 3-month resistance exercise intervention improves walking distance, #HRQOL, symptoms of anxiety and depression, and grip strength among adults with lingering symptoms following #COVID19 infection. Published in @jamanetworkopen.com and @infectiousdisease.bsky.social.

https://bit.ly/45yr2q2
Resistance Exercise Aids Physical and Mental Health Following COVID-19 Infection
A personalized 3-month resistance exercise program improved walking distance and HRQOL in adults with persistent COVID-19 symptoms.
bit.ly
February 7, 2026 at 8:05 PM
hematologyadvisor.bsky.social
Register today for the 11th Annual ONA Summit. Free live virtual #CE event March 20-21. Dynamic and interactive presentations led by expert faculty. Designed for #Oncology nurses in all roles. https://bit.ly/4qjckL5
February 7, 2026 at 7:01 PM
hematologyadvisor.bsky.social
Umbilical cord blood transplantation, combined with uldMTX as a GVHD prophylaxis, provides superior survival for patients with high-risk #MDS and #AML. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/4k6jyR3

#leusm
Cord Blood Transplantation Shows Superior Survival for MDS
The uldMTX regimen may strike an optimal balance, preserving a potent graft-versus-leukemia effect while mitigating the treatment-related toxicities that can delay engraftment or increase non-relapse mortality.
bit.ly
February 6, 2026 at 9:50 PM
hematologyadvisor.bsky.social
“These findings align with prior mechanistic research demonstrating increased CNI-related #cancerrisk and represents novel comparative safety data between these treatment modalities,” @jeffsparks.bsky.social of @harvardmed.bsky.social wrote.

https://bit.ly/4bqSrhm

#HemOnc
CNI vs Belimumab for Lupus Nephritis May Carry Higher Cancer Risk
Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs belimumab.
bit.ly
February 5, 2026 at 10:06 PM
hematologyadvisor.bsky.social
The presence of MUC4 genetic mutations significantly increases the risk for developing thromboses in individuals with #paroxysmalNocturnalHemoglobinuria. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/3Z2nnx1

#PNH
MUC4 Mutations Linked to Elevated Risk for Thrombosis in Patients With PNH
The incidence of thrombotic events was statistically significantly greater among patients with MUC4 gene mutations compared with those without MUC4 mutations (P =.003).
bit.ly
February 4, 2026 at 5:54 PM
hematologyadvisor.bsky.social
Interventions may be necessary to reach #cancersurvivors in neighborhoods with low #socioeconomic status to help them be able to successfully return to work. Published in @oncologynurseadv.bsky.social.

https://bit.ly/469EPU1
Cancer Survivors With Lower SES Find Return to Work More Challenging
Socioeconomic status of cancer survivors or the neighborhood in which they live has a significant effect on their perceived work ability and functional outcomes. Cancer survivors with low socioeconomic status or who live in low SES neighborhoods need in...
bit.ly
February 3, 2026 at 5:48 PM
hematologyadvisor.bsky.social
A new system for staging of systemic AL #amyloidosis, the AL International Staging System (AL-ISS) was developed and externally validated in a study with findings reported in @ascopost.bsky.social Journal of Clinical Oncology.

https://bit.ly/3NJDvRt
New AL-ISS Model Validated for Prognosis in AL Amyloidosis
Researchers developed and externally validated the AL International Staging System (AL-ISS), a new system for staging of systemic AL amyloidosis.
bit.ly
February 2, 2026 at 9:30 PM
hematologyadvisor.bsky.social
A new point-of-care platform is gaining attention as a promising tool to improve #coagulation testing for people with #hemophilia A. From @rarediseaseadvisor.bsky.social.

https://bit.ly/462BmXm

#HemOnc
EnzySystem Shows Promising Results in Hemophilia Testing
Patients favored using the system at home, especially for self-monitoring, while healthcare professionals supported both home and clinic use.
bit.ly
February 1, 2026 at 6:39 PM
hematologyadvisor.bsky.social
A specially designed, age-appropriate, cross-cultural questionnaire can be useful in assessing the health-related quality of life in adolescents and young adults with #cancer. Published in @jamanetworkopen.com.

https://bit.ly/4qL0vOM

#HRQOL #AYACancer
Questionnaire Assesses Issues Relevant to Adolescents/Young Adults With Cancer
Researchers developed a 30-item questionnaire to measure health-related quality of life of adolescent and young adult patients with cancer. Researchers developed a 30-item questionnaire to measure health-related quality of life of adolescent and young a...
bit.ly
January 31, 2026 at 7:47 PM
hematologyadvisor.bsky.social
Ethical considerations in research should always prioritize the well-being of the fetus and the #pregnant mother. From @rarediseaseadvisor.bsky.social.

https://bit.ly/45BCp0l

#ClinicalTrials
Ethics-Based Guidelines Fundamental to Clinical Trials Involving Pregnant Women
Ethical considerations in research should always prioritize the well-being of the fetus and the pregnant mother.
bit.ly
January 30, 2026 at 10:14 PM
hematologyadvisor.bsky.social
CD20-targeting bispecific antibodies including epcoritamab and glofitamab may be effective against R/R #DLBCL in the real-world setting, though survival rates were lower than those noted in pivotal clinical trials. Published in @bloodjournals.hematology.org.

https://bit.ly/3ZFUiYc

#lymsm
CD20-Targeting Bispecific Antibodies May Be Effective in Patients With DLBCL in Real-World Settings
Researchers determined epcoritamab and glofitamab may be effective in treating patients with relapsed or refractory DLBCL in the real-world setting.
bit.ly
January 29, 2026 at 10:09 PM
hematologyadvisor.bsky.social
Patients with #bloodcancer eligible for #hospice care emphasize the importance of access to #transfusion over other services. Published in @jamanetworkopen.com.

https://bit.ly/4k6hl8d

#HemOnc
Patients With Terminal Blood Cancer Stress Need for Transfusion Access in Hospice Care, Survey Finds
Survey results showed patients with hematologic cancers eligible for hospice care prioritize access to transfusion over other services.
bit.ly
January 28, 2026 at 9:55 PM
hematologyadvisor.bsky.social
"Many patient populations with hereditary conditions such as #thalassemia have lived w the disease for their entire life, so it’s not surprising that they report high levels of confidence in health-related knowledge" @devasharma.bsky.social of @vumedicine.bsky.social.

https://bit.ly/4t4hyN6

#ASH25
Significant Barriers to Health Literacy Exist for Patients With Thalassemia
Researchers determined there may be overestimation of disease understanding and barriers to health literacy among patients with thalassemia.
bit.ly
January 27, 2026 at 8:35 PM
hematologyadvisor.bsky.social
A long-term analysis from the UK TTP Registry, published in @bloodjournals.hematology.org, shows that regular ADAMTS13 prophylaxis reduces acute episodes and prevents end-organ damage in congenital thrombotic #thrombocytopenicPurpura.

https://bit.ly/49Ncnse

#cTTP
Regular ADAMTS13 Prophylaxis Reduces Acute Events and Organ Damage in cTTP
Researchers determined regular ADAMTS13 prophylaxis reduces acute episodes and prevents end-organ damage in cTTP.
bit.ly
January 26, 2026 at 9:14 PM
hematologyadvisor.bsky.social
A long-term analysis from the UK TTP Registry, published in @bloodjournals.hematology.org, shows that regular ADAMTS13 prophylaxis reduces acute episodes and prevents end-organ damage in congenital thrombotic #thrombocytopenicPurpura.

https://bit.ly/49Ncnse

#cTTP
Regular ADAMTS13 Prophylaxis Reduces Acute Events and Organ Damage in cTTP
Researchers determined regular ADAMTS13 prophylaxis reduces acute episodes and prevents end-organ damage in cTTP.
bit.ly
January 26, 2026 at 9:14 PM
hematologyadvisor.bsky.social
High patient-to-nursing ratios and an unsafe workplace environment are some of the grievances cited by the striking #nurses. From @clinicaladvisor.bsky.social.

https://bit.ly/45jbFl3

#NurseStrike
New York City Nurses Go On Strike
New York City nurses are working without a contract, which expired on December 31, 2025. Their grievances include an unsafe workplace and high patient-to-nursing ratios. The nurses are working without a contract, which expired on December 31, 2025. Thei...
bit.ly
January 25, 2026 at 6:23 PM
hematologyadvisor.bsky.social
Men are twice as likely as women to have stage III #multiplemyeloma at diagnosis and appear to have a greater #tumor burden than women. Published in @cancertherapyadv.bsky.social

https://bit.ly/45Quhcg
In Multiple Myeloma, Men May Have Greater Tumor Burden Than Women
Men are twice as likely as women to have stage III multiple myeloma at diagnosis, and appear to have a greater tumor burden.
bit.ly
January 24, 2026 at 7:54 PM
hematologyadvisor.bsky.social
The @fda.gov has accepted the supplemental Biologics License Application for ropeginterferon alfa-2b-njft for the treatment of adult patients with essential #thrombocythemia. From @medicalprofref.bsky.social.

https://bit.ly/4qwQuoj
Ropeginterferon Alfa-2b Under Review for Essential Thrombocythemia
The FDA has accepted the supplemental Biologics License Application for ropeginterferon alfa-2b-njft for the treatment of adults with essential thrombocythemia.
bit.ly
January 23, 2026 at 10:12 PM
hematologyadvisor.bsky.social
The use of IV iron dextran was more cost-effective and resulted in greater quality-adjusted life years compared with oral iron to treat heavy menstrual bleeding-related iron deficiency #anemia. Published in @bloodjournals.hematology.org.

https://bit.ly/45fm5lO
IV Iron Dextran Results in Higher QALYs vs Oral Iron
IV iron dextran was more cost-effective and resulted in greater QALYs compared with oral iron to treat heavy menstrual bleeding-related iron deficiency anemia.
bit.ly
January 22, 2026 at 9:51 PM
hematologyadvisor.bsky.social
📅 Plan your year in #hemOnc! To help you stay aware of events relevant to #hematology professionals, here is the 2026 calendar for various professional meetings and conferences.

View the full list here: 🩸 https://bit.ly/3NoRnk6

#MedicalConferences
Hematology Conference Calendar 2026
To help you stay aware of events relevant to hematology professionals, here is the 2026 calendar for various professional meetings and conferences.
bit.ly
January 21, 2026 at 8:46 PM
hematologyadvisor.bsky.social
Among patients with newly diagnosed, advanced-stage classical #HodgkinLymphoma, the novel BrECADD combination may represent a new standard treatment option. Presented at #ASH25 by @ferdinandusj.bsky.social. From @cancertherapyadv.bsky.social.

https://bit.ly/45HWHVP

#ASH2025 #lymsm
BrECADD May Be a Standard Therapy Option in Newly Diagnosed, Advanced-Stage HL - Hematology Advisor
Researchers compared the safety and efficacy of BrECADD vs eBEACOPP, a standard regimen, in the newly diagnosed, advanced-stage classical HL setting.
bit.ly
January 20, 2026 at 5:48 PM